PCVX as reported
- Net Income
- −$1.06B
Net Income · +94% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$894M
Free Cash Flow · +88% year on year · trailing twelve months to Q2 2026
- EPS
- −$7.63
EPS · +86% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$1.06B | +94% | Q2 2026 |
| EPS | −$7.63 | +86% | Q2 2026 |
| ROE | −30% | n/a | Q2 2026 |
| ROA | −27% | n/a | Q2 2026 |
| Free Cash Flow | −$894M | +88% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Vaxcyte, Inc. (PCVX) - Net IncomeNet IncomeVaxcyte, Inc. (PCVX)